KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding: 2017-2024

Historic Shares Outstanding for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $91.4 million.

  • Aquestive Therapeutics' Shares Outstanding rose 33.43% to $121.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 33.43%. This contributed to the annual value of $91.4 million for FY2024, which is 33.39% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Shares Outstanding stood at $91.4 million for FY2024, which was up 33.39% from $68.5 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Shares Outstanding registered a high of $91.4 million during FY2024, and its lowest value of $34.6 million during FY2020.
  • For the 3-year period, Aquestive Therapeutics' Shares Outstanding averaged around $71.6 million, with its median value being $68.5 million (2023).
  • Data for Aquestive Therapeutics' Shares Outstanding shows a peak YoY surged of 33.39% (in 2024) over the last 5 years.
  • Aquestive Therapeutics' Shares Outstanding (Yearly) stood at $34.6 million in 2020, then grew by 19.26% to $41.2 million in 2021, then skyrocketed by 32.98% to $54.8 million in 2022, then increased by 25.00% to $68.5 million in 2023, then skyrocketed by 33.39% to $91.4 million in 2024.